Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0PBDFF
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ADC3-18
|
|||||
| Synonyms |
ADC3 18
Click to Show/Hide
|
|||||
| Organization |
BeiGene Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Colorectal cancer [ICD11:2B91]
Investigative
Non-small cell lung cancer [ICD11:2C25]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
7.9
|
|||||
| Structure |
|
|||||
| Antibody Name |
Patritumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-3 (ERBB3)
|
Antigen Info | ||||
| Payload Name |
ADC 3-18 payload
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
ADC 3-18 linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.